Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) saw strong trading volume on Tuesday . 251,889 shares changed hands during mid-day trading, an increase of 15% from the previous session’s volume of 218,180 shares.The stock last traded at $21.39 and had previously closed at $21.10.

A number of equities analysts have issued reports on the company. Zacks Investment Research downgraded Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Raymond James Financial Inc. assumed coverage on Blueprint Medicines Corp. in a report on Friday, May 27th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Blueprint Medicines Corp. currently has an average rating of “Buy” and an average price target of $28.50.

The company’s market capitalization is $553.13 million. The firm’s 50-day moving average is $19.58 and its 200 day moving average is $18.15.

Blueprint Medicines Corp. (NASDAQ:BPMC) last released its earnings results on Tuesday, May 10th. The company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.13. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $3.24 million. Blueprint Medicines Corp.’s quarterly revenue was up 961.5% on a year-over-year basis. Analysts anticipate that Blueprint Medicines Corp. will post ($3.10) EPS for the current fiscal year.

In related news, CEO Jeffrey W. Albers sold 17,000 shares of the business’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $20.03, for a total transaction of $340,510.00. Following the completion of the transaction, the chief executive officer now owns 92,486 shares in the company, valued at approximately $1,852,494.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.